Sage Rock Capital Management’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q3
Sell
-105,691
Closed -$1.05M 220
2021
Q2
$1.05M Sell
105,691
-468,109
-82% -$4.71M 0.14% 159
2021
Q1
$5.71M Sell
573,800
-448,156
-44% -$4.77M 0.69% 50
2020
Q4
$11M Buy
+1,021,956
New +$10.5M 1.83% 12

Other funds holding STLN

Sage Rock Capital Management's STLN Position: Q3 2021 in Review

Sage Rock Capital Management sold out of Starling Oncology Institute, Inc. Common Stock (STLN) in Q3 2021, closing a stake of 105,691 shares — an estimated $1.05M sold.

Sage Rock Capital Management first reported a position in STLN in Q4 2020 and held it in 3 quarters. The position peaked at $11M in Q4 2020. 51 funds tracked by Wall St. Rank hold STLN as of Q3 2021.

  • Sage Rock Capital Management reported no remaining Starling Oncology Institute, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Sage Rock Capital Management sold 105,691 Starling Oncology Institute, Inc. Common Stock shares in Q3 2021, an estimated $1.05M.
  • Sage Rock Capital Management first reported a position in Starling Oncology Institute, Inc. Common Stock in Q4 2020 and held it in 3 quarters.
  • Sage Rock Capital Management's Starling Oncology Institute, Inc. Common Stock position peaked at $11M in Q4 2020.
  • 51 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q3 2021.

Based on Sage Rock Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.